| Business Summary | | Novoste
Corporation
has
developed
the
Beta-Cath
System,
a
hand-held
device
to
deliver
beta,
or
low
penetration,
radiation
to
the
site
of
a
treated
blockage
in
a
coronary
artery
to
decrease
the
likelihood
of
restenosis.
Restenosis,
the
renarrowing
of
a
previously
treated
artery,
is
the
major
limitation
of
percutaneous
coronary
intervention
(PTCA),
a
procedure
used
by
interventional
cardiologists
to
open
blocked
coronary
arteries.
The
Beta-Cath
System
has
been
shown
to
reduce
the
incidence
of
restenosis
in-patients
who
are
being
treated
for
blocked
stents,
or
in-stent
restenosis.
The
Beta-Cath
System
is
designed
to
fit
well
with
techniques
currently
used
by
interventional
cardiologists
in
the
cath
lab.
It
is
a
hand-held
device
that
hydraulically
delivers
beta
radiation
sources
through
a
closed-end
catheter
to
the
area
of
the
coronary
artery
injured
by
the
immediately
preceding
PTCA
procedure. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NOVT
is
a
medical
device
company
engaged
in
commercializing
the
Beta-Cath
System,
an
intraluminal
beta
radiation
catheter
delivery
system
designed
to
reduce
restenosis.
For
the
six
months
ended
6/30/01,
revenues
totaled
$26.6
million,
up
from
$2
million.
Net
loss
fell
31%
to
$9.9
million.
Revenues
reflect
the
sale
of
the
Beta-Cath
(TM)
System
in
the
U.S.
Net
loss
was
partially
offset
higher
support
personnel,
trade
show
and
consulting
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Thomas Weldon, 45 Chairman | -- | -- | William Hawkins, 47 Pres,
CEO, Director | $423K | $808K | Edwin Cordell, Jr., 42 CFO | -- | -- | Daniel Hall, 53 VP,
Gen. Counsel | -- | -- | Robert Wood, Jr., 46 VP
of Sales | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|